References

The RIG-I-like receptor IFIH1/MDA5 is a dermatomy-ositis-specific autoantigen identified by the anti-CADM-140 antibody

10.1093/rheumatology/kep375 · 2010 · External reference

Editorial: anti-MDA5-positive dermatomyositis

10.3389/fmed.2022.941370 · 2022 · External reference

Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cy-clophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis

10.1002/art.41105 · 2020 · External reference

Clinical features and survival analysis of 40 cases of anti-MDA5 antibody-positive dermatomyositis complicated with interstitial lung disease

10.1186/s13075-025-03485-z · 2025 · External reference

Management and prognosis of anti-MDA5 dermatomyo-sitis: insights from a national multicenter cohort

10.3390/biomedicines14030709 · 2026 · External reference

10.12659/msm.940251

10.12659/msm.940251 · External reference

Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis

10.1093/rheumatology/key188 · 2018 · External reference

plasma exchange in the inten-sive care unit: a narrative review

10.1007/s00134-022-06793-z · 2022 · External reference

Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment

10.1093/rheumatology/keaa123 · 2020 · External reference

Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis

10.3109/14397595.2014.981945 · 2015 · External reference

Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease

10.1056/nejmc1900045 · 2019 · External reference